Skip to content
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.

Japan Policy and Regulation

New rules, public consultations, subsidies and regulator actions in Japan, in English.

  1. Japan asks doctors to stop starting new patients on Kissei's avacopan drug

    Japan's health ministry has asked doctors to withhold Kissei's avacopan from new patients and, as a rule, to consider stopping or switching those already taking it, after a panel found the approval data may be unreliable.

  2. Japan Prices iPS-Derived Heart Patch ReHeart at ¥53.2mn

    Chuikyo, Japan's insurance-pricing panel, set a ¥53.2mn reimbursement price for ReHeart, Cuorips's iPS cell-derived cardiac tissue sheet for severe heart failure, but sales cannot begin until the official listing takes effect on September 1.